Screener
Mirum Pharmaceuticals, Inc. MIRM Unrealized Gains on Investments
Unrealized Gains on Investments at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.
The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001759425-26-000045
| Line item | Amortized Cost | Unrealized Gain | Unrealized Loss | Estimated Fair Value |
|---|---|---|---|---|
| U.S. government bonds | 73,414 | 1 | (142) | 73,273 |
| Agency bonds | 16,500 | — | (69) | 16,431 |
| Commercial paper | 17,970 | — | — | 17,970 |
| Total cash equivalents and investments | $493,743 | $6 | $(472) | $493,277 |
| Classified as: | ||||
| Cash equivalents | $262,684 | |||
| Short-term investments | 107,563 | |||
| Long-term investments | 123,030 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Mirum Pharmaceuticals, Inc.'s unrealized gains on investments?
- Mirum Pharmaceuticals, Inc. (MIRM) reported unrealized gains on investments of $6K in Q2 2026.
- What does unrealized gains on investments mean?
- The total unrealized gains on investments, typically related to available-for-sale securities.
Ask your AI about Mirum Pharmaceuticals, Inc.'s unrealized gains on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude